BioCryst Expects FY23 Orladeyo Revenue To Be No Less Than $320M; Operating Expenses Are Expected To Be Flat To 2022 At Approximately $375M
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals expects its FY23 revenue from Orladeyo to be no less than $320M, with operating expenses expected to remain flat to 2022 at approximately $375M. The company anticipates reductions in R&D spending in 2023 due to the discontinuation of the BCX9930 and BCX9250 programs in 2022 and the delay in the BCX10013 clinical program. However, this will be offset by increases in SG&A to support the U.S. launch and global expansion of Orladeyo.
August 04, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioCryst's FY23 revenue forecast for Orladeyo and flat operating expenses, along with reduced R&D spending due to discontinuation of certain programs, could impact its stock positively in the short term.
The company's revenue forecast for Orladeyo and flat operating expenses indicate a positive financial outlook. Additionally, the reduction in R&D spending due to the discontinuation of certain programs could lead to cost savings, potentially boosting the company's profitability and positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100